Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther 2013;36:462–470.
-
2. Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther 2007;30:336–344.
-
3. Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg 2013;40:28–34.
-
4. Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med 2010;24:1452–1457.
-
5. Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. Vet Comp Oncol 2007;5:38–46.
-
6. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31:220–229.
-
7. Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014;94:265–301.
-
8. Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 2002;300:925–931.
-
9. Greenwood-Van Meerveld B, Gibson MS, Johnson AC, et al. NK1 receptor-mediated mechanisms regulate colonic hyper-sensitivity in the guinea pig. Pharmacol Biochem Behav 2003;74:1005–1013.
-
10. Onori L, Agio A, Taddei G, et al. Peristalsis regulation by tachykin NK1 receptors in the rabbit isolated distal colon. Am J Physiol Gastrointest Liver Physiol 2003;285:G325–G331.
-
11. AVMA. US pet ownership and demographics sourcebook. Schaumburg, Ill: AVMA, 2012.
-
12. Meesters R, Voswinkel S. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry. J Appl Bioanal 2018;4:67–73.
-
13. Kenward H, Elliott J, Lee T, et al. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Vet Res 2017;13:244.
-
14. de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 2007;68:48–56.
-
15. Steinbach JR, MacGuire J, Chang S, et al. Assessment of preoperative maropitant citrate use in macaque (Macaca fasicularis & Macaca mulatta) neurosurgical procedures. J Med Primatol 2018;47:178–184.
-
16. Cram RL, Juchau MR, Fouts JR. Differences in hepatic drug metabolism in various rabbit strains before and after pretreatment with phenobarbital. Proc Soc Exp Biol Med 1965;118:872–875.
-
17. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980;8:165–176.
-
18. Deckers N, Ruigrok CA, Verhoeve HP, et al. Comparison of pain response after subcutaneous injection of two maropitant formulations to Beagle dogs. Vet Rec Open 2018;5:e000262.
-
19. Narishetty ST, Galvan B, Coscarelli E, et al. Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection. Vet Ther 2009;10:93–102.
-
20. Pfizer. Cerenia (maropitant citrate) injectable solution for cats. In: Freedom of information summary. New York: Pfizer Inc, 2012;141–262.
-
21. Nakamura A, Tanaka T, Imanishi A, et al. Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptors. J Pharmacol Sci 2011;117:106–115.
Advertisement
Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)
Abstract
OBJECTIVE
To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus).
ANIMALS
11 sexually intact (3 males and 8 females) adult rabbits.
PROCEDURES
Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored.
RESULTS
Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment.
CONCLUSIONS AND CLINICAL RELEVANCE
Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.
Contributor Notes
Powered by PubFactory